Report Detail

Pharma & Healthcare Global (United States, European Union and China) Pulmonary Arterial Hypertension Treatment Market Research Report 2019-2025

  • RnM3669893
  • |
  • 14 August, 2019
  • |
  • Global
  • |
  • 117 pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global (United States, European Union and China) Pulmonary Arterial Hypertension Treatment Market Research Report 2019-2025

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Vasodilators
      • 1.3.3 Phosphodiesterase 5 (PDE 5) Inhibitors
      • 1.3.4 Endothelin Receptor Antagonists (ERA)
      • 1.3.5 Soluble Guanylate Cyclase (SGC) Stimulator
    • 1.4 Market Segment by Application
      • 1.4.1 Global Pulmonary Arterial Hypertension Treatment Market Share by Application (2019-2025)
      • 1.4.2 Hospital Pharmacies
      • 1.4.3 Retail Pharmacies
      • 1.4.4 Online Pharmacies
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Pulmonary Arterial Hypertension Treatment Market Size
      • 2.1.1 Global Pulmonary Arterial Hypertension Treatment Revenue 2014-2025
      • 2.1.2 Global Pulmonary Arterial Hypertension Treatment Sales 2014-2025
    • 2.2 Pulmonary Arterial Hypertension Treatment Growth Rate by Regions
      • 2.2.1 Global Pulmonary Arterial Hypertension Treatment Sales by Regions 2014-2019
      • 2.2.2 Global Pulmonary Arterial Hypertension Treatment Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Pulmonary Arterial Hypertension Treatment Sales by Manufacturers
      • 3.1.1 Pulmonary Arterial Hypertension Treatment Sales by Manufacturers 2014-2019
      • 3.1.2 Pulmonary Arterial Hypertension Treatment Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Pulmonary Arterial Hypertension Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Pulmonary Arterial Hypertension Treatment Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.3 Pulmonary Arterial Hypertension Treatment Price by Manufacturers
    • 3.4 Key Manufacturers Pulmonary Arterial Hypertension Treatment Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Pulmonary Arterial Hypertension Treatment Market
    • 3.6 Key Manufacturers Pulmonary Arterial Hypertension Treatment Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Vasodilators Sales and Revenue (2014-2019)
      • 4.1.2 Phosphodiesterase 5 (PDE 5) Inhibitors Sales and Revenue (2014-2019)
      • 4.1.3 Endothelin Receptor Antagonists (ERA) Sales and Revenue (2014-2019)
      • 4.1.4 Soluble Guanylate Cyclase (SGC) Stimulator Sales and Revenue (2014-2019)
    • 4.2 Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Type
    • 4.3 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type
    • 4.4 Pulmonary Arterial Hypertension Treatment Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Pulmonary Arterial Hypertension Treatment Sales by Application

    6 United States

    • 6.1 United States Pulmonary Arterial Hypertension Treatment Breakdown Data by Company
    • 6.2 United States Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
    • 6.3 United States Pulmonary Arterial Hypertension Treatment Breakdown Data by Application

    7 European Union

    • 7.1 European Union Pulmonary Arterial Hypertension Treatment Breakdown Data by Company
    • 7.2 European Union Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
    • 7.3 European Union Pulmonary Arterial Hypertension Treatment Breakdown Data by Application

    8 China

    • 8.1 China Pulmonary Arterial Hypertension Treatment Breakdown Data by Company
    • 8.2 China Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
    • 8.3 China Pulmonary Arterial Hypertension Treatment Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Pulmonary Arterial Hypertension Treatment Breakdown Data by Company
    • 9.2 Rest of World Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
    • 9.3 Rest of World Pulmonary Arterial Hypertension Treatment Breakdown Data by Application
    • 9.4 Rest of World Pulmonary Arterial Hypertension Treatment Breakdown Data by Countries
      • 9.4.1 Rest of World Pulmonary Arterial Hypertension Treatment Sales by Countries
      • 9.4.2 Rest of World Pulmonary Arterial Hypertension Treatment Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 GlaxoSmithKline plc
      • 10.1.1 GlaxoSmithKline plc Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.1.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.1.5 GlaxoSmithKline plc Recent Development
    • 10.2 Eli Lilly and Company
      • 10.2.1 Eli Lilly and Company Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.2.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.2.5 Eli Lilly and Company Recent Development
    • 10.3 Pfizer Inc.Actelion Inc
      • 10.3.1 Pfizer Inc.Actelion Inc Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.3.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.3.5 Pfizer Inc.Actelion Inc Recent Development
    • 10.4 United Therapeutic Corporation
      • 10.4.1 United Therapeutic Corporation Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.4.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.4.5 United Therapeutic Corporation Recent Development
    • 10.5 SteadyMed Ltd
      • 10.5.1 SteadyMed Ltd Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.5.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.5.5 SteadyMed Ltd Recent Development
    • 10.6 Gilead Sciences, Inc
      • 10.6.1 Gilead Sciences, Inc Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.6.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.6.5 Gilead Sciences, Inc Recent Development
    • 10.7 Teva Pharmaceuticals Inc
      • 10.7.1 Teva Pharmaceuticals Inc Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.7.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.7.5 Teva Pharmaceuticals Inc Recent Development
    • 10.8 Bayer AG
      • 10.8.1 Bayer AG Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Pulmonary Arterial Hypertension Treatment
      • 10.8.4 Pulmonary Arterial Hypertension Treatment Product Introduction
      • 10.8.5 Bayer AG Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Pulmonary Arterial Hypertension Treatment Sales Channels
      • 11.2.2 Pulmonary Arterial Hypertension Treatment Distributors
    • 11.3 Pulmonary Arterial Hypertension Treatment Customers

    12 Market Forecast

    • 12.1 Global Pulmonary Arterial Hypertension Treatment Sales and Revenue Forecast 2019-2025
    • 12.2 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Type
    • 12.3 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Application
    • 12.4 Pulmonary Arterial Hypertension Treatment Forecast by Regions
      • 12.4.1 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Pulmonary Arterial Hypertension Treatment Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.
      In 2019, the market size of Pulmonary Arterial Hypertension Treatment is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Pulmonary Arterial Hypertension Treatment.

      This report studies the global market size of Pulmonary Arterial Hypertension Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Pulmonary Arterial Hypertension Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      GlaxoSmithKline plc
      Eli Lilly and Company
      Pfizer Inc.Actelion Inc
      United Therapeutic Corporation
      SteadyMed Ltd
      Gilead Sciences, Inc
      Teva Pharmaceuticals Inc
      Bayer AG

      Market Segment by Product Type
      Vasodilators
      Phosphodiesterase 5 (PDE 5) Inhibitors
      Endothelin Receptor Antagonists (ERA)
      Soluble Guanylate Cyclase (SGC) Stimulator

      Market Segment by Application
      Hospital Pharmacies
      Retail Pharmacies
      Online Pharmacies

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Pulmonary Arterial Hypertension Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Pulmonary Arterial Hypertension Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Pulmonary Arterial Hypertension Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025


      Summary:
      Get latest Market Research Reports on Pulmonary Arterial Hypertension Treatment. Industry analysis & Market Report on Pulmonary Arterial Hypertension Treatment is a syndicated market report, published as Global (United States, European Union and China) Pulmonary Arterial Hypertension Treatment Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Pulmonary Arterial Hypertension Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,280.00
      $4,920.00
      $6,560.00
      2,693.54
      4,040.30
      5,387.07
      2,957.78
      4,436.66
      5,915.55
      349,306.88
      523,960.32
      698,613.76
      235,310.15
      352,965.23
      470,620.30
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report